Highlights Catalyst Pharmaceuticals, Inc.

Equities

CPRX

US14888U1016

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
15.2 ^USD	+1.00%		+0.53%	-9.58%

Apr. 10	Catalyst Pharmaceuticals Insider Sold Shares Worth $392,000, According to a Recent SEC Filing	MT
Apr. 04	Certain Stock Options of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE(R) (Vamorolone) in the United States	Mar. 14	DJ
Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy	Mar. 13	CI
Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024	Feb. 29	CI
Catalyst Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Catalyst Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Catalyst Pharmaceuticals Seeks Acquisitions	Jan. 10	CI
Top Stories at Midday: December US Nonfarm Payrolls Rise; ISM US Services Index Falls; CVS Names Finance Chief; Tesla to Recall Vehicles in China; Catalyst Prices Stock Offering	Jan. 05	MT
Dydo Group Unit Files New Drug Application for Autoimmune Disease Treatment Candidate	Dec. 19	MT
Catalyst Pharmaceuticals, Inc. Announces Firapse New Drug Application Submitted in Japan by Partner DyDo Pharma	Dec. 18	CI
Catalyst Pharmaceuticals Q3 Adjusted Profit, Revenue Rise; Lifts 2023 Guidance	Nov. 09	MT
Earnings Flash (CPRX) CATALYST PHARMACEUTICALS Reports Q3 EPS $0.49	Nov. 08	MT
Earnings Flash (CPRX) CATALYST PHARMACEUTICALS Posts Q3 Revenue $102.7M, vs. Street Est of $100.4M	Nov. 08	MT
Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023	Nov. 08	CI
Tranche Update on Catalyst Pharmaceuticals, Inc.'s Equity Buyback Plan announced on March 22, 2021.	Nov. 08	CI
Catalyst Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Catalyst Pharmaceuticals Gets Two US Patent Allowances For Firdapse	Nov. 02	MT
Catalyst Pharmaceuticals, Inc. Receives Two New U.S. Patent Allowances for FIRDAPSE	Nov. 02	CI
US FDA approves Santhera's drug for rare muscular dystrophy	23-10-26	RE
Catalyst Pharmaceuticals, Inc. Reports FDA Approval of AGAMREE® for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals	23-10-26	CI
Catalyst Pharmaceuticals Says Supplemental Application for Neuromuscular Disorder Treatment Accepted for Review by FDA	23-10-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Catalyst Pharmaceuticals, Inc: Optimistic scenario

March 06, 2023 at 10:44 am EST